Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | MPI | P34949 | 1/20 | 0.31 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14882384 | 0.98 | HSD17B10 (0.32) | HSD17B10SMN1; SMN2RAPGEF4MAPTPKM | |
| SCHEMBL14225400 | 0.86 | SMN1; SMN2 (0.30) | SMN1; SMN2 | |
| SCHEMBL19521963 | 0.81 | ALDH1A1 (0.36) | SMN1; SMN2PKM | |
| SCHEMBL22675159 | 0.80 | GPR35 (0.33) | HSD17B10SMN1; SMN2GPR35 | |
| SCHEMBL16767803 | 0.80 | — | — | |
| SCHEMBL16767802 | 0.80 | RAPGEF4 (0.37) | SMN1; SMN2RAPGEF4MAPTPKM | |
| SCHEMBL17226536 | 0.80 | — | — | |
| SCHEMBL14882574 | 0.79 | SKP2 (0.40) | MAPTPKM | |
| SCHEMBL20110430 | 0.77 | BRD4 (0.34) | SMN1; SMN2MAPTPKM | |
| SCHEMBL14882390 | 0.77 | SKP2 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2719702-B1 | ELECTROCHROMIC ELEMENT | CANON KK (JP) | 2016-05-11 | — | — | EP | disclosed |
| EP-2588484-B1 | ORGANIC COMPOUND AND ELECTROCHROMIC DEVICE INCLUDING THE SAME | CANON KK (JP) | 2015-11-04 | — | — | EP | disclosed |
| US-9001408-B2 | Electrochromic device | CANON KABUSHIKI KAISHA (JP) | 2015-04-07 | — | — | US | disclosed |
| US-9001408-B2 | Electrochromic device | CANON KABUSHIKI KAISHA (JP) | 2015-04-07 | — | — | US | disclosed |
| US-8982443-B2 | Organic compound and electrochromic device including the same | CANON KABUSHIKI KAISHA (JP) | 2015-03-17 | — | — | US | disclosed |
| US-8982443-B2 | Organic compound and electrochromic device including the same | CANON KABUSHIKI KAISHA (JP) | 2015-03-17 | — | — | US | disclosed |
| EP-2719702-A1 | ELECTROCHROMIC ELEMENT | Canon Kabushiki Kaisha (JP) | 2014-04-16 | — | — | EP | disclosed |
| US-20130100517-A1 | NOVEL ORGANIC COMPOUND AND ELECTROCHROMIC DEVICE INCLUDING THE SAME | CANON KABUSHIKI KAISHA (JP) | 2013-04-25 | — | — | US | disclosed |
| US-20130100517-A1 | NOVEL ORGANIC COMPOUND AND ELECTROCHROMIC DEVICE INCLUDING THE SAME | CANON KABUSHIKI KAISHA (JP) | 2013-04-25 | — | — | US | disclosed |
| US-20120314272-A1 | ELECTROCHROMIC DEVICE | CANON KABUSHIKI KAISHA (JP) | 2012-12-13 | — | — | US | disclosed |
| US-20120314272-A1 | ELECTROCHROMIC DEVICE | CANON KABUSHIKI KAISHA (JP) | 2012-12-13 | — | — | US | disclosed |
| WO-2012002185-A1 | NOVEL ORGANIC COMPOUND AND ELECTROCHROMIC DEVICE INCLUDING THE SAME | CANON KABUSHIKI KAISHA (JP) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130100517-A1 | NOVEL ORGANIC COMPOUND AND ELECTROCHROMIC DEVICE INCLUDING THE SAME | CCNL2, DNMT3L, ARL1 | HSD17B10 1421/4885SMN1; SMN2 3079/4885RAPGEF4 2877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.